Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma

Clinical Trial ID NCT02073123

Rank	Title	Journal	Year	PubWeight™‹?›
1	Molecular Pathways: Targeting IDO1 and Other Tryptophan Dioxygenases for Cancer Immunotherapy.	Clin Cancer Res	2015	1.09
2	Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications.	Oncoimmunology	2015	1.06
3	Trial watch: IDO inhibitors in cancer therapy.	Oncoimmunology	2014	1.01
4	IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance.	Trends Immunol	2016	0.96
5	Small molecule drugs with immunomodulatory effects in cancer.	Hum Vaccin Immunother	2015	0.86
6	The past, present and future of immunotherapy against tumor.	Transl Lung Cancer Res	2015	0.85
7	Trial Watch-Small molecules targeting the immunological tumor microenvironment for cancer therapy.	Oncoimmunology	2016	0.84
8	Targeting the indoleamine 2,3-dioxygenase pathway in cancer.	J Immunother Cancer	2015	0.84
9	Early Carcinogenesis Involves the Establishment of Immune Privilege via Intrinsic and Extrinsic Regulation of Indoleamine 2,3-dioxygenase-1: Translational Implications in Cancer Immunotherapy.	Front Immunol	2014	0.80
10	Recent Advances in Immunotherapy in Metastatic NSCLC.	Front Oncol	2016	0.79
11	Inflammation Models of Depression in Rodents: Relevance to Psychotropic Drug Discovery.	Int J Neuropsychopharmacol	2016	0.78
12	Tryptophan PET Imaging of the Kynurenine Pathway in Patient-Derived Xenograft Models of Glioblastoma.	Mol Imaging	2016	0.78
13	Combination Approaches with Immune-Checkpoint Blockade in Cancer Therapy.	Front Oncol	2016	0.77